Relay Therapeutics, Inc.

Contributing Author

Recent Articles by Relay Therapeutics, Inc.

Nov-04	Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates RLAY RLAY -5.71% GlobeNewswire
Nov-02	Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November RLAY -5.83% GlobeNewswire
Oct-28	Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 RLAY GlobeNewswire
Sep-01	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September RLAY GlobeNewswire
Aug-06	Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates RLAY GlobeNewswire
Jul-30	Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 RLAY +5.88% GlobeNewswire
May-27	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June RLAY GlobeNewswire
May-20	Relay Therapeutics Announces Pricing of Public Offering of Common Stock RLAY GlobeNewswire
May-19	Relay Therapeutics Announces Proposed Public Offering of Common Stock RLAY GlobeNewswire
May-19	Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies RLAY GlobeNewswire
May-05	Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates RLAY GlobeNewswire
Apr-29	Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 RLAY GlobeNewswire
Apr-27	Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer RLAY GlobeNewswire
Apr-02	Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 RLAY +16.43% GlobeNewswire
Mar-16	Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 RLAY GlobeNewswire
Feb-26	Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones RLAY RLAY +12.01% GlobeNewswire
Feb-23	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March RLAY GlobeNewswire
Feb-19	Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 RLAY GlobeNewswire
Feb-04	Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 RLAY GlobeNewswire
Feb-03	Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer RLAY +6.38% GlobeNewswire
Dec-12	Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 RLAY GlobeNewswire
Nov-06	Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates RLAY RLAY -7.35% GlobeNewswire
Nov-03	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November RLAY GlobeNewswire
Oct-30	Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 RLAY GlobeNewswire
Aug-28	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September RLAY GlobeNewswire
Aug-07	Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates RLAY RLAY -7.74% GlobeNewswire
Jul-31	Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 RLAY GlobeNewswire
Jun-11	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors RLAY GlobeNewswire
Jun-02	Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 RLAY +6.00% GlobeNewswire
May-29	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June RLAY GlobeNewswire
May-08	Relay Therapeutics to Participate in Two Upcoming Investor Conferences RLAY GlobeNewswire
May-05	Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates RLAY RLAY -5.12% GlobeNewswire

Relay Therapeutics, Inc.

Recent Articles by Relay Therapeutics, Inc.

Upgrade your Finviz experience